A Case of Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Treated with TAS-102 with Bevacizumab
Hasegawa, J.; Noura, S.; Hirota, M.; Matsumura, T.; Yasuyama, A.; Takata, A.; Koga, C.; Murakami, M.; Kameda, C.; Oda, N.; Kawabata, R.; Morishima, H.; Shimizu, J.; Matsunami, N.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 43(12): 2289-2291
2016
ISSN/ISBN: 0385-0684 PMID: 28133298 Document Number: 687199
A 51-year-oldwoman with lung, liver, andd istant lymph node metastases from sigmoidcolon cancer was treatedusing TAS-102 with bevacizumab as fourth-line chemotherapy. There was a 35%decrease in the size of target lesions after the first 4 cycles of therapy, and disease control has been maintained for 9 months. The only Grade 3 or worse adverse event experiencedwas neutropenia. In patients with refractory colorectal cancer, the combination of TAS-102 with bevacizumab might be an effective andsafe treatment.
Document emailed within 1 workday
Related Documents
Takano, J.; Matsuhashi, N.; Takahashi, T.; Tanahashi, T.; Matsui, S.; Imai, H.; Tanaka, Y.; Yamaguchi, K.; Yoshida, K. 2018: A Case of Metastatic Colorectal Cancer with Brain Metastasis Treated with Combined TFTD and Bevacizumab Therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(2): 318-320Imaizumi, H.; Ishibashi, K.; Okada, N.; Tajima, Y.; Amano, K.; Hatano, S.; Kuwabara, K.; Sobajima, J.; Ishiguro, T.; Ohsawa, T.; Kumamoto, K.; Kumagai, Y.; Haga, N.; Ishida, H. 2012: Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(12): 2185-2188
Arakawa, S.; Horiguchi, A.; Tomishige, H.; Kawabe, N.; Nagata, H.; Ishihara, S.; Ito, M.; Asano, Y.; Ito, R.; Isetani, M.; Shimizu, K.; Kamio, K.; Kawai, T.; Yasuoka, H.; Imaeda, Y. 2018: Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(4): 649-651
Tural, D.; Selcukbiricik, F.; Erdamar, S.; Ozkurt, C.Unlu.; Yanmaz, T.; Mandel, N.Molinas.; Serdengeçti, Süheyla. 2013: Association KRAS G13D tumor mutated outcome in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab Hepato-Gastroenterology 60(125): 1035-1040
Koike, J.; Ushigome, M.; Funahashi, K.; Shiokawa, H.; Kaneko, T.; Arai, K.; Matsuda, S.; Kagami, S.; Suzuki, T.; Kurihara, A.; Shimada, H.; Kaneko, H. 2014: Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer Hepato-Gastroenterology 61(136): 2222-2226
Shirato, T.; Aoki, T.; Yazawa, M. 2011: Surgical treatment for metastatic lung cancer treated with bevacizumab Kyobu Geka. Japanese Journal of Thoracic Surgery 64(7): 579-581
Chen, C.; Sun, P.; Ye, S.; Weng, H.-W.; Dai, Q.-S. 2014: Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: a meta-analysis Journal of Buon: Official Journal of the Balkan Union of Oncology 19(4): 917-924
Denić, K.; Tarabar, D.; Obradovic, S.; Ristić, M.; Spasić, J.; Radosavljević, D.; Ugrešić, N. 2016: Biochemical liver function test parameter levels in relation to treatment response in liver metastatic colorectal patients treated with FOLFOX4 with or without bevacizumab Srpski Arhiv Za Celokupno Lekarstvo 144(11-12): 615-620
Li, J.; Xu, J-Ming.; Li, J.; Zhang, X-Dong.; Bai, Y.; Chu, Y-Ping.; Wang, Y-Hua.; Liu, D-Qi.; Jin, M-Lin.; Shen, L. 2008: Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer Zhonghua Zhong Liu Za Zhi 30(3): 225-227
Kato, K. 2011: Development of oral drugs in the standard therapy for metastatic colorectal cancer patients Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 3): 454-458
Sehnalová, I.; Říhová, B.; Demlová, R. 2019: Bevacizumab treatment in metastatic colorectal carcinoma - an economic perspective Ceska a Slovenska Farmacie: Casopis Ceske Farmaceuticke Spolecnosti a Slovenske Farmaceuticke Spolecnosti 68(2): 43-47
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954
Ota, T.; Takeshima, N.; Takizawa, K. 2011: Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly? European Journal of Gynaecological Oncology 32(5): 471-475
Machida, T.; Nishimura, M.; Yamada, H.; Oka, Y.; Nakadai, E.; Suda, R.; Okaniwa, A.; Kobayashi, S.; Kataoka, M.; Yanagisawa, S.; Kaiho, T. 2019: A Case of Pancreatic Metastasis from Colon Cancer Successfully Treated with Capecitabine/Oxaliplatin plus Bevacizumab Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(4): 793-795
Fujita, T.; Kawasaki, K.; Ohno, M.; Kanaji, S.; Kobayashi, I.; Ueno, K.; Tsuchida, S.; Osawa, M.; Fujino, Y.; Kanbara, Y.; Nakamura, T. 2009: A successfully resected case of rectal cancer with liver metastases treated with mFOLFOX6 and bevacizumab Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(4): 663-666
Ito, S.; Ichikawa, R.; Kure, K.; Honjo, K.; Aoki, J.; Okazawa, Y.; Mizukoshi, K.; Ro, H.; Kawai, M.; Takehara, K.; Okubo, H.; Ishiyama, S.; Sugimoto, K.; Komiyama, H.; Takahashi, M.; Yaginuma, Y.; Kojima, Y.; Goto, M.; Tomiki, Y.; Sakamoto, K. 2014: A case of cecum colon cancer with lymph node metastasis successfully treated with XELOX plus bevacizumab Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(11): 1425-1428
Nakano, M.; Kameyama, H.; Shimada, Y.; Hashimoto, Y.; Hosoi, M.; Nakano, M.; Nogami, H.; Hanyu, T.; Takizawa, K.; Ishikawa, T.; Sakata, J.; Kobayashi, T.; Minagawa, M.; Kosugi, S.; Koyama, Y.; Wakai, T. 2014: A case of descending colon cancer with multiple liver metastases effectively treated with capecitabine/oxaliplatin (CapeOX) and bevacizumab Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1785-1787
Yabe, N.; Murai, S.; Shimizu, H.; Kitasato, K.; Yoshikawa, T.; Oto, I.; Nakadai, J.; Hasegawa, H.; Kitagawa, Y. 2013: Recurrent rectal cancer with multiple liver and lung metastases treated effectively with oxaliplatin and capecitabine plus bevacizumab chemotherapy-a case report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(12): 1834-1836
Saltz, L. 2009: Current role of bevacizumab in colorectal cancer Clinical Advances in Hematology and Oncology: H&o 7(6): 375-376
Miyake, Y.; Ikeda, K.; Murakami, M.; Oka, Y.; Nezu, R.; Kurokawa, E.; Kikkawa, N. 2015: Two Cases of Bowel Perforation during Chemotherapy with Bevacizumab to Metastatic Rectal Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(Suppl 1): 75-78